Vyndamax (tafamidis 61mg)
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Conditions
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Trial Timeline
Jun 29, 2021 → Dec 31, 2026
NCT ID
NCT04801329About Vyndamax (tafamidis 61mg)
Vyndamax (tafamidis 61mg) is a pre-clinical stage product being developed by Pfizer for ATTR-CM (Transthyretin Amyloid Cardiomyopathy). The current trial status is active. This product is registered under clinical trial identifier NCT04801329. Target conditions include ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04801329 | Pre-clinical | Active |
Competing Products
3 competing products in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Acoramidis (356 mg film-coated tablets) | Bayer | Pre-clinical | 20 |